BackAtossa Therapeutics Overview

Atossa Therapeutics Total Liabilities

Track Atossa Therapeutics's total liabilities ($5.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$5.45M
20.07% YoYΔ $-1.37M vs prior year quarter

Peer trimmed avg / median

Loading

Atossa Therapeutics Total Liabilities History

Loading

Atossa Therapeutics vs. peers: Total Liabilities Comparison

Loading

Atossa Therapeutics Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Atossa Therapeutics (ATOS) FAQ

Atossa Therapeutics (ATOS) currently reports a total liabilities of $5.5M as of June 2026. That compares with $6.8M in the prior-year period — down 20.1% year over year. Use the charts on this page to explore Atossa Therapeutics's total liabilities history and peer comparisons.

Atossa Therapeutics's total liabilities decreased from $6.8M to $5.5M — a 20.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Atossa Therapeutics reported $5.5M in total liabilities as of June 2026. That compares with $6.8M in the prior-year period — down 20.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $5.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Atossa Therapeutics, and consider following ATOS for alerts when major investors trade the stock.

Atossa Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $5.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATOS with unrelated industries.